We find that MIR200CHG and YB-1 bind stably in breast cancer cells, and the changes in the expression of MIR200CHG do not affect the level of YB-1 mRNA but affect the post translational modification status of YB-1. Here, MIR200CHG is linked to breast carcinoma.